Brazil's president announced tirzepatida could come to the public health system. Here's what that actually involves and how long it might take.
The Promise and What It Actually Said
In early 2024, President Lula announced plans to include tirzepatida in Brazil's public healthcare system. The announcement made headlines across the country, sparking hope among the millions of Brazilians who currently pay out of pocket for the medication. But here's what many people don't realize: a presidential announcement and an actual public health policy are two very different things.
When a president says something will happen in healthcare, it typically means the Ministry of Health has been asked to explore the possibility. The actual process of turning that political will into a program that delivers medication to patients involves multiple government agencies, technical evaluations, budget allocations, and supply chain decisions. Each step takes time, and any one of them can delay or derail the process.
The Ministry of Health, specifically the departments that handle pharmaceutical policies and health technology assessment, would be responsible for moving this promise forward. They've handled similar promises before, with mixed results. Following official Ministry of Saúde channels and staying informed through resources like TirzeBlog helps patients separate genuine progress from political theater.
How the SUS Decides What Drugs to Cover
If tirzepatida ever reaches SUS, it will first have to go through CONITEC—the National Committee for Health Technology Incorporation. This is the technical body that evaluates every new medication proposed for inclusion in Brazil's public healthcare system. No drug enters SUS without CONITEC's recommendation.
CONITEC looks at several factors: how well the medication works compared to existing options, whether the price makes sense relative to the benefits, how the drug would impact the overall SUS budget, and how many people would actually need it. They also consider disease burden—who suffers from the condition and how severely does it affect their lives?
The evaluation process isn't quick. From the moment a formal application is submitted to CONITEC to when a final recommendation comes out, months typically pass. Applications can come from drug manufacturers, government agencies, or medical societies. If Eli Lilly formally applies for tirzepatida's inclusion, the clock starts. But there's no guarantee the application will be submitted, and even if it is, CONITEC might recommend against it, request more studies, or approve it with restrictions.
Mounjaro vs. Zepbound: Registration Status in Brazil
One key detail that affects everything is which formulation of tirzepatida we're talking about. Mounjaro is the brand name for tirzepatida used in treating type 2 diabetes, while Zepbound is the same molecule marketed for obesity treatment. Both come in injectable pen form, but they're registered with ANVISA separately.
ANVISA, Brazil's health regulatory agency, has granted registration to Mounjaro for diabetes indication. The registration status of Zepbound in Brazil is less straightforward at this time. For a medication to be purchased and distributed through SUS at scale, the drug needs active ANVISA registration and a manufacturer willing to supply the public system.
If only one formulation has proper registration, the other cannot be officially distributed through public channels. This matters because the indication approved by ANVISA determines what SUS can legally cover. Even if the health ministry wants to provide tirzepatida for obesity, they can only do so if ANVISA has approved that specific indication for that specific brand name.
Supply, Distribution, and Production Realities
Even if CONITEC approves tirzepatida and ANVISA registration is in place, actually getting the medication to patients requires solving some practical problems. Tirzepatida pens require refrigeration—specifically storage between 2°C and 8°C. This cold chain requirement exists throughout transportation and storage.
The Ministry of Saúde would need to establish procurement agreements with Eli Lilly or authorized distributors. Government bulk purchasing can lower prices significantly compared to retail, but negotiations take time. The Brazilian government has experience with this for other biologics, including various insulins, which also require cold chain management.
Global supply of tirzepatida has faced constraints, with demand often outpacing manufacturing capacity. For SUS to receive consistent supplies, production and distribution agreements must prioritize Brazil's public system. This is another negotiation that could face delays or complications.
The difference between a drug being "included in SUS" and actually being "available at pharmacies and clinics" is enormous. Inclusion means the government commits to purchasing and providing the medication. Availability means the drug is actually in stock at healthcare facilities across this massive country. Brazil has included medications in SUS before that took years to reach patients due to distribution problems.
Who Would Actually Qualify and Who Might Not
SUS coverage doesn't mean universal access for everyone who wants the medication. The public system has historically used eligibility criteria to determine who receives certain treatments. For obesity medications specifically, SUS coverage has been extremely limited.
Common approaches include setting BMI thresholds—typically requiring a BMI of 35 or higher, or 30 or higher with related health conditions like diabetes or hypertension. Previous treatment failures might be required, meaning patients would need to try other options first before accessing tirzepatida. These criteria aim to prioritize those with the greatest medical need and conditions most likely to benefit.
If demand exceeds what SUS can supply, rationing becomes inevitable. This means longer waitlists, priority systems, and unfortunately, many people who technically qualify but still can't access the medication. The gap between approved indication and actual clinical access can be significant in resource-limited settings.
International Comparisons
Brazil isn't the first country considering how to make tirzepatida accessible through public healthcare. The UK's NHS has taken steps toward covering semaglutide products for obesity management after NICE evaluations. The United States has FDA-approved tirzepatida but public coverage through Medicare for weight loss specifically remains limited.
Other countries that have achieved public coverage typically did so through negotiated pricing agreements—prices that would be difficult to achieve in Brazil given the economic constraints and negotiating power of the SUS system. International examples show the path is possible but rarely fast. From regulatory approval to public coverage, most countries have taken multiple years.
What Brazil can learn is that successful public coverage requires more than political will. It needs structured negotiations, realistic budget planning, and phased rollout strategies. The countries that managed this well started with limited populations and expanded as systems matured.
A Realistic Timeline and What Patients Should Expect
Here's the honest answer: even if everything proceeds smoothly, actual access to tirzepatida through SUS likely remains years away. A realistic timeline from announcement to implementation would probably be three to five years minimum, and that's being optimistic.
After presidential announcements, formal applications to CONITEC must be submitted. Then evaluations, recommendations, budget negotiations, procurement agreements, and distribution planning all need to happen. Each phase involves government bureaucracy, political considerations, and potential delays.
In the short term, patients relying on tirzepatida should plan as if SUS coverage doesn't exist yet. Continue working with healthcare providers on current treatment strategies. In the medium term, watching official Ministry of Saúde communications and staying informed through trusted sources like TirzeBlog can help patients understand when and if real progress occurs.
For those who can afford it, the private market remains the most reliable path to access tirzepatida in Brazil for the foreseeable future. Monitoring developments doesn't mean waiting passively—it means being prepared to adjust plans as the situation evolves.
FAQ
How long does the CONITEC evaluation process typically take?
The CONITEC evaluation process can take several months to over a year from formal application to final recommendation, depending on complexity and whether additional information is requested.
Does ANVISA registration automatically mean a drug can be sold in Brazil?
ANVISA registration allows commercial distribution in the private market, but it does not automatically mean the drug will be purchased or provided through SUS. Separate government procurement decisions are required.
Which formulation of tirzepatida has better chances of entering SUS first?
Mounjaro, approved for type 2 diabetes, may have a clearer path since diabetes treatments have more established coverage criteria in SUS. Obesity indication through Zepbound would require separate evaluation and approval pathways.
Sources
Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always consult your doctor before starting, changing or stopping any treatment.
Ozempro — Monitor GLP-1
Track your weight and your progress
Log weight, measurements and labs and see your progress in clear charts — because progress you don't measure is invisible progress.
or download the app
